{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T00:01:58Z","timestamp":1793750518293,"version":"4.6.1"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009017","name":"ALS Society of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009017","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009744","name":"Eshelman Institute for Innovation, University of North Carolina at Chapel Hill","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009744","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1097737"],"award-info":[{"award-number":["1097737"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000196","name":"Canada Foundation for Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008582","name":"McGill University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008582","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004270","name":"Kungliga Tekniska H\u00f6gskolan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004270","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008762","name":"Genome Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["875510"],"award-info":[{"award-number":["875510"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000971","name":"ALS Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000971","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016040","name":"Takeda Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016040","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000092","name":"Ontario Genomics Institute","doi-asserted-by":"publisher","award":["OGI-196"],"award-info":[{"award-number":["OGI-196"]}],"id":[{"id":"10.13039\/501100000092","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000188","name":"Royal Society of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["RF1AG057443"],"award-info":[{"award-number":["RF1AG057443"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["106169\/ZZ14\/Z"],"award-info":[{"award-number":["106169\/ZZ14\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["New Biotechnology"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.nbt.2021.07.001","type":"journal-article","created":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T20:51:03Z","timestamp":1625691063000},"page":"1-8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Opinion: Independent third-party entities as a model for validation of commercial antibodies"],"prefix":"10.1016","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5906-025X","authenticated-orcid":false,"given":"Carl","family":"Laflamme","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aled M.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5497-0243","authenticated-orcid":false,"given":"Anita E.","family":"Bandrowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7806-5662","authenticated-orcid":false,"given":"Peter S.","family":"McPherson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nbt.2021.07.001_bib0005","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/521274a","article-title":"Reproducibility crisis: blame it on the antibodies","volume":"521","author":"Baker","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.nbt.2021.07.001_bib0010","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/518027a","article-title":"Reproducibility: Standardize antibodies used in research","volume":"518","author":"Bradbury","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.nbt.2021.07.001_bib0015","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/nmeth.3995","article-title":"A proposal for validation of antibodies","volume":"13","author":"Uhlen","year":"2016","journal-title":"Nat Methods"},{"key":"10.1016\/j.nbt.2021.07.001_bib0020","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2020.1794421","article-title":"The Antibody Society?\"s antibody validation webinar series","volume":"12","author":"Voskuil","year":"2020","journal-title":"MAbs"},{"key":"10.1016\/j.nbt.2021.07.001_bib0025","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/483531a","article-title":"Drug development: raise standards for preclinical cancer research","volume":"483","author":"Begley","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.nbt.2021.07.001_bib0030","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nmeth0107-13","article-title":"ProteomeBinders: planning a European resource of affinity reagents for analysis of the human proteome","volume":"4","author":"Taussig","year":"2007","journal-title":"Nat Methods"},{"key":"10.1016\/j.nbt.2021.07.001_bib0035","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1074\/mcp.R800013-MCP200","article-title":"A genecentric Human Protein Atlas for expression profiles based on antibodies","volume":"7","author":"Berglund","year":"2008","journal-title":"Mol Cell Proteomics"},{"key":"10.1016\/j.nbt.2021.07.001_bib0040","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.216416","article-title":"The path to VICTORy - a beginner?\"s guide to success using commercial research antibodies","author":"Goodman","year":"2018","journal-title":"J Cell Sci"},{"key":"10.1016\/j.nbt.2021.07.001_bib0045","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1042\/BJ20121742","article-title":"Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies","volume":"453","author":"Davies","year":"2013","journal-title":"Biochem J"},{"key":"10.1016\/j.nbt.2021.07.001_bib0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/BCJ20170802","article-title":"Development of phospho-specific Rab protein antibodies to monitor in vivo activity of the LRRK2 Parkinson?\"s disease kinase","volume":"475","author":"Lis","year":"2018","journal-title":"Biochem J"},{"key":"10.1016\/j.nbt.2021.07.001_bib0055","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13024-017-0229-1","article-title":"A validated antibody panel for the characterization of tau post-translational modifications","volume":"12","author":"Ercan","year":"2017","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.nbt.2021.07.001_bib0060","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.48363","article-title":"Implementation of an antibody characterization procedure and application to the major ALS\/FTD disease gene C9ORF72","volume":"8","author":"Laflamme","year":"2019","journal-title":"Elife"},{"key":"10.1016\/j.nbt.2021.07.001_bib0065","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1471-2121-15-6","article-title":"CiteAb: a searchable antibody database that ranks antibodies by the number of times they have been cited","volume":"15","author":"Helsby","year":"2014","journal-title":"BMC Cell Biol"},{"key":"10.1016\/j.nbt.2021.07.001_bib0070","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1074\/mcp.M113.035600","article-title":"Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics","volume":"13","author":"Fagerberg","year":"2014","journal-title":"Mol Cell Proteomics"},{"key":"10.1016\/j.nbt.2021.07.001_bib0075","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/s41592-018-0179-8","article-title":"A high-throughput pipeline for validation of antibodies","volume":"15","author":"Sikorski","year":"2018","journal-title":"Nat Methods"},{"key":"10.1016\/j.nbt.2021.07.001_bib0080","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1002\/pmic.201400441","article-title":"Version 4.0 of PaxDb: protein abundance data, integrated across model organisms, tissues, and cell-lines","volume":"15","author":"Wang","year":"2015","journal-title":"Proteomics"},{"key":"10.1016\/j.nbt.2021.07.001_bib0085","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-019-1186-3","article-title":"Next-generation characterization of the Cancer cell line encyclopedia","volume":"569","author":"Ghandi","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.nbt.2021.07.001_bib0090","series-title":"DepMap, Broad","year":"2019"},{"key":"10.1016\/j.nbt.2021.07.001_bib0095","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1517\/14728222.2016.1135132","article-title":"Accelerating medicines partnership: Alzheimer?\"s disease (AMP-AD) knowledge portal aids alzheimer?\"s drug discovery through open data sharing","volume":"20","author":"Hodes","year":"2016","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.nbt.2021.07.001_bib0100","doi-asserted-by":"crossref","first-page":"232","DOI":"10.12688\/f1000research.4966.1","article-title":"Commercial antibodies and their validation","volume":"3","author":"Voskuil","year":"2014","journal-title":"F1000Res"},{"key":"10.1016\/j.nbt.2021.07.001_bib0105","doi-asserted-by":"crossref","first-page":"134","DOI":"10.12688\/f1000research.6555.1","article-title":"The Resource Identification Initiative: a cultural shift in publishing","volume":"4","author":"Bandrowski","year":"2015","journal-title":"F1000Res"},{"key":"10.1016\/j.nbt.2021.07.001_bib0110","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.neuron.2016.04.030","article-title":"RRIDs: a simple step toward improving reproducibility through rigor and transparency of experimental methods","volume":"90","author":"Bandrowski","year":"2016","journal-title":"Neuron"},{"key":"10.1016\/j.nbt.2021.07.001_bib0115","first-page":"e1150","article-title":"Improving transparency and scientific rigor in academic publishing","volume":"2","author":"Prager","year":"2019","journal-title":"Cancer Rep (Hoboken)"},{"key":"10.1016\/j.nbt.2021.07.001_bib0120","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/s41592-020-0915-8","article-title":"Change-makers bring on recombinant antibodies","volume":"17","author":"Marx","year":"2020","journal-title":"Nat Methods"},{"key":"10.1016\/j.nbt.2021.07.001_bib0125","series-title":"Helping address the reproducibility crisis in research","author":"Abcam","year":"2020"}],"container-title":["New Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871678421000704?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871678421000704?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T10:05:06Z","timestamp":1761732306000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871678421000704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":25,"alternative-id":["S1871678421000704"],"URL":"https:\/\/doi.org\/10.1016\/j.nbt.2021.07.001","relation":{},"ISSN":["1871-6784"],"issn-type":[{"value":"1871-6784","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Opinion: Independent third-party entities as a model for validation of commercial antibodies","name":"articletitle","label":"Article Title"},{"value":"New Biotechnology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nbt.2021.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}